^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ZNF217 mutation

    i
    Other names: ZNF217, Zinc Finger Protein 217, ZABC1
    Entrez ID:
    7764
    Related biomarkers:
    Mutation
    Others
    Associations

    News

    Trials
    12ms
    Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial. (PubMed, MedComm (2020))
    This multicenter, single-arm, phase II clinical trial (NCT04034589) evaluated the efficacy and safety of pyrotinib combined with fulvestrant in patients with HR-positive/HER2-positive metastatic breast cancer who had experienced trastuzumab treatment failure. Importantly, no grade 4 or higher treatment-related adverse events or deaths were reported, indicating a favorable safety profile. In conclusion, the combination of pyrotinib and fulvestrant demonstrated promising antitumor activity and acceptable safety in HR-positive/HER2-positive metastatic breast cancer patients.
    P2 data • Journal • Tumor mutational burden • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • ZNF217 (Zinc Finger Protein 217)
    |
    HER-2 positive • HR positive • TMB-L • ZNF217 mutation
    |
    Herceptin (trastuzumab) • Irene (pyrotinib) • fulvestrant